CA3186564A1 - Method for treating graft versus host disease caused by hematopoietic stem cell transplantation - Google Patents

Method for treating graft versus host disease caused by hematopoietic stem cell transplantation

Info

Publication number
CA3186564A1
CA3186564A1 CA3186564A CA3186564A CA3186564A1 CA 3186564 A1 CA3186564 A1 CA 3186564A1 CA 3186564 A CA3186564 A CA 3186564A CA 3186564 A CA3186564 A CA 3186564A CA 3186564 A1 CA3186564 A1 CA 3186564A1
Authority
CA
Canada
Prior art keywords
days
compound
gekg
group
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3186564A
Other languages
English (en)
French (fr)
Inventor
Cheung Ling Cheng
Yanping Zhao
Hongjun Wang
Weiting ZHONG
Jing Li
Jing Zhao
Weina LIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Tide Pharmaceutical Co Ltd
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of CA3186564A1 publication Critical patent/CA3186564A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3186564A 2020-07-22 2021-07-21 Method for treating graft versus host disease caused by hematopoietic stem cell transplantation Pending CA3186564A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010713637.0 2020-07-22
CN202010713637 2020-07-22
PCT/CN2021/107575 WO2022017412A1 (zh) 2020-07-22 2021-07-21 治疗造血干细胞移植后的移植物抗宿主病的方法

Publications (1)

Publication Number Publication Date
CA3186564A1 true CA3186564A1 (en) 2022-01-27

Family

ID=79728482

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3186564A Pending CA3186564A1 (en) 2020-07-22 2021-07-21 Method for treating graft versus host disease caused by hematopoietic stem cell transplantation

Country Status (11)

Country Link
US (1) US20230285393A1 (pt)
EP (1) EP4186508A1 (pt)
JP (1) JP2023535035A (pt)
KR (1) KR20230043891A (pt)
CN (1) CN116322670A (pt)
AU (1) AU2021313124A1 (pt)
BR (1) BR112023001049A2 (pt)
CA (1) CA3186564A1 (pt)
IL (1) IL299985A (pt)
TW (2) TW202216691A (pt)
WO (1) WO2022017412A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4393917A1 (en) * 2021-09-18 2024-07-03 Beijing Tide Pharmaceutical Co., Ltd. Solid form of rho-associated protein kinase inhibitor or solvate thereof, preparation method and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010222848A1 (en) * 2009-03-09 2011-10-20 Surface Logix, Inc. Rho kinase inhibitors
EP2903618B1 (en) * 2012-10-05 2022-06-01 Kadmon Corporation, LLC Rho kinase inhibitors
WO2018039539A1 (en) * 2016-08-26 2018-03-01 Lycera Corporation Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
ES2969536T3 (es) 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
KR102469161B1 (ko) * 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
WO2019000682A1 (zh) * 2017-06-30 2019-01-03 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途

Also Published As

Publication number Publication date
TW202327609A (zh) 2023-07-16
EP4186508A1 (en) 2023-05-31
AU2021313124A1 (en) 2023-03-09
IL299985A (en) 2023-03-01
TW202216691A (zh) 2022-05-01
JP2023535035A (ja) 2023-08-15
WO2022017412A1 (zh) 2022-01-27
CN116322670A (zh) 2023-06-23
KR20230043891A (ko) 2023-03-31
BR112023001049A2 (pt) 2023-03-07
US20230285393A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
US11945804B2 (en) Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
KR101483831B1 (ko) 대장염 치료용 조성물 및 방법
WO2021248095A1 (en) Heterocyclic compounds and methods of use thereof
US20220233538A1 (en) Method for treating idiopathic pulmonary fibrosis
WO2021248079A1 (en) Heterocyclic compounds and methods of use thereof
US11292799B2 (en) Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
US11981681B2 (en) Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitors
WO2020156189A1 (zh) 喜树碱衍生物及其水溶性前药、包含其的药物组合物及其制备方法和用途
EP4186508A1 (en) Method for treating graft versus host disease caused by hematopoietic stem cell transplantation
US20230399332A1 (en) IMIDAZO[1,2-a]PYRAZINE OR PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND USE THEREOF
US20220211703A1 (en) Method for treating cough by using diaminopyrimidine compound
US11299497B2 (en) Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
CA3138238A1 (en) Method for treating endometriosis-associated pain by using diaminopyrimidine compound
US20240217952A1 (en) Treatment of graft-versus-host disease with inhibitors of bet family bdii bromodomain
WO2024097932A1 (en) Compounds and their use for treatment of hemoglobinopathies
WO2024124000A1 (en) Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain